Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME

NCT02363621 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

101

Enrollment

OTHER

Sponsor class

Conditions

Diabetic Macular Edema

Interventions

DRUG: Ranibizumab 0.3 mg
DRUG: Aflibercept 2.0 mg

Sponsor

Arshad Khanani

Collaborators

[object Object]